BGISEQ-500 is an industry leading high-throughput sequencing solution, powered by combinatorial Probe-Anchor Synthesis (cPAS) and improved DNA Nanoballs (DNB) technology. The cPAS chemistry works by incorporating a fluorescent probe to a DNA anchor on the DNB, followed by high-resolution digital imaging. This combination of linear amplification and DNB technology reduces the error rate while enhancing the signal. In addition, the size of the DNB is controlled in such a way that only one DNB is bound per active site. This patterned array technology not only provides sequencing accuracy, but it also increases the chip utilization and sample density.
Each BGISEQ-500 can process two chips in a single run, with each chip capable of running different conditions on independent samples. In addition, we have developed two different types of chips: The high-throughput chip is well suited for analyzing many different sample types and provides large read output per run (200 Gb). The fast-throughput chip is optimized for short turn-around-time applications, such as clinical exomes, or for more economical runs where less data is required. These flexibilities will meet a variety of customers'sequencing needs, and bring the best value to our users.
BGISEQ-500 provides a clear end-to-end sequencing work flow and allows for complete analysis of samples from input to the final result in as little as 24 hours when combined with the optional automatic library preparation and sample loading instruments.
BGISEQ-500 is equipped with an intelligent, touch-sensitive interface providing simple, user-friendly operation. The automated tracking capabilities for samples, chips and reagents makes lab information management simple, secure and traceable.
BGISEQ-500 has an optional automatic library preparation and sample loading system supporting a variety of library preparation strategies. For each library method, specific reagent cartridges are formulated to maximize system performance and make the operation smooth and seamless. We've built flexibility into the system so, as applications expand into new scientific and clinical areas, so will BGISEQ-500.
*Clinical use is subject to regulatory approval.